Screener
Zevra Therapeutics, Inc. ZVRA Income Tax
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Interest and other income, net | 2,565 | 2,378 | 6,155 | 2,921 |
| Total other (expense) income | (3,983) | 147,945 | (11,324) | 151,390 |
| Income before income taxes | 12,794 | 76,906 | 57,599 | 74,989 |
| Income tax expense | (4,042) | (2,199) | (10,957) | (3,381) |
| Net income | $8,752 | $74,707 | $46,642 | $71,608 |
| Net income per share of common stock: | ||||
| Basic | $0.14 | $1.24 | $0.76 | $1.20 |
| Diluted | $0.14 | $1.21 | $0.74 | $1.16 |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s income tax?
- Zevra Therapeutics, Inc. (ZVRA) reported income tax of $4.04M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s income tax changed year-over-year?
- Zevra Therapeutics, Inc.'s income tax increased by 83.8% year-over-year, from $2.2M to $4.04M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s income tax?
- Over 3 years (2021 to 2025), Zevra Therapeutics, Inc.'s income tax has grown at a 366.4% compound annual growth rate (CAGR), from $34K to $3.45M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Zevra Therapeutics, Inc.'s income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude